Stuart Mossman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stuart Mossman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Benjamin Mossman
A Department of Neurology, Wellington Hospital , Wellington , New Zealand
2 shared publications- Duncan Smyth
Neuromuscular Diseases, UCL, London, UK
2 shared publications Evan Jolliffe
A Department of Neurology, Wellington Hospital , Wellington , New Zealand
2 shared publicationsKatie Thorne
A Department of Neurology, Wellington Hospital , Wellington , New Zealand
2 shared publications- Mark Weatherall
University of Otago Wellington, Wellington, New Zealand
2 shared publications Tawhai Moss
A Department of Neurology, Wellington Hospital , Wellington , New Zealand
2 shared publications
Latest Publications
- 16 July 2019
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 139 (9) , 759-768
Gentamicin vestibulotoxicity with modern systemic dosing regimens: a prospective study using video-oculography
Objectives: To determine the incidence of gentamicin vestibulotoxicity with current dosing regimens, and to evaluate the feasibility of routine video-oculography on all patients given gentamicin. Materials and methods: In this prospective incidence study serial horizontal vestibulo-ocular reflex (HVOR) gain measurements were recorded using video-oculography on adult inpatients receiving intravenous gentamicin. The primary outcome was the proportion of patients developing impairment of their HVOR gain. Results: After exclusions, 42 patients were included in the analysis. Three patients (7.1%) developed asymptomatic vestibulotoxicity, exact 95% confidence interval 1.5–19.5%. In two of these patients the deficit resolved within several hours. No patients developed symptomatic vestibulotoxicity. There was no evidence for a generalised reduction in group HVOR gain with time. HVOR gain was not associated with total gentamicin dose, dynamic visual acuity or subjective imbalance. Conclusions and significance: Gentamicin may cause reversible, asymptomatic vestibulotoxicity. Video-oculography may be useful to monitor for vestibulotoxicity in patients treated with gentamcin; however, testing all patients routinely may be challenging.
- 16 July 2019
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 139 (9) , 759-768
Gentamicin vestibulotoxicity with modern systemic dosing regimens: a prospective study using video-oculography
Objectives: To determine the incidence of gentamicin vestibulotoxicity with current dosing regimens, and to evaluate the feasibility of routine video-oculography on all patients given gentamicin. Materials and methods: In this prospective incidence study serial horizontal vestibulo-ocular reflex (HVOR) gain measurements were recorded using video-oculography on adult inpatients receiving intravenous gentamicin. The primary outcome was the proportion of patients developing impairment of their HVOR gain. Results: After exclusions, 42 patients were included in the analysis. Three patients (7.1%) developed asymptomatic vestibulotoxicity, exact 95% confidence interval 1.5–19.5%. In two of these patients the deficit resolved within several hours. No patients developed symptomatic vestibulotoxicity. There was no evidence for a generalised reduction in group HVOR gain with time. HVOR gain was not associated with total gentamicin dose, dynamic visual acuity or subjective imbalance. Conclusions and significance: Gentamicin may cause reversible, asymptomatic vestibulotoxicity. Video-oculography may be useful to monitor for vestibulotoxicity in patients treated with gentamcin; however, testing all patients routinely may be challenging.
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Gentamicin vestibulotoxicity is uncommon with modern dosing regimens: a prospective study using video head impulse testing (P6.043)
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Gentamicin vestibulotoxicity is uncommon with modern dosing regimens: a prospective study using video head impulse testing (P6.043)